TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06660069
Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothpaste containing 0.454% w/w SnF2.
Study: NCT05694533
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup administered orally on Days 1 and 15
Study: NCT05414292
Drug: Rapamune (sirolimus) 1Mg Tablet
Normalized name: sirolimus 1 MG [Rapamune]
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
Study: NCT06670222
Drug: Arsenic Trioxide (ATO)
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study treatment: oral Arsenic 5d/7 for 21 days over a 28-day cycle, three doses tested (0.10 mg/kg, 0.15 mg/kg and 0.20 mg/kg).~Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme, 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients.~Tolerability will be assessed after one treatment cycle. Response will be assessed after 3 cycles of treatment. Responders may continue study treatment until progression or limiting toxicity. Limiting toxicity is defined as any grade III/IV extra-hematological toxicity or grade IV hematological toxicity lasting more than 25 days.
Study: NCT05661253
Drug: 25 ml of bupivacaine 0.25% via serratus anterior block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
Study: NCT06612710
Drug: extracellular vesicles derived from human induced neural stem cell for intravenous injection
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）
Study: NCT06612710
Drug: a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: extracellular vesicles placebo (4×10\^9 particles/kg)
Study: NCT05448989
Drug: 1% atropine 5+3
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A method for myopia control using high-concentration atropine
Study: NCT06397911
Drug: FB825
Normalized name: FB825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Study: NCT06667076
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered subcutaneously.
Study: NCT06667076
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib tablet will be administered orally.
Study: NCT06667076
Drug: Chemotherapy: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered through IV infusion.
Study: NCT06667076
Drug: Chemotherapy: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered through IV infusion.
Study: NCT05572515
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered subcutaneously.
Study: NCT05572515
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered orally.
Study: NCT05572515
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered subcutaneously.
Study: NCT05572515
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
Study: NCT05572515
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered intravenously.
Study: NCT06503614
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500mg IV
Study: NCT06503614
Drug: Monalizumab
Normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monalizumab 1500mg IV
Study: NCT06422520
Drug: BGB-C354
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT06422520
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT06604858
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
Study: NCT06604858
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
Study: NCT06604858
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
Study: NCT05242419
Drug: Sodium Chloride Injection
Normalized name: Sodium Chloride Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection
Study: NCT05242419
Drug: Huperzine A Injection
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A Injection
Study: NCT05905783
Drug: Izokibep
Normalized name: Izokibep
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04542382
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet.
Study: NCT05835713
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
Study: NCT05835713
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
Study: NCT06671912
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06671912
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06671912
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06671912
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04810091
Drug: Telotristat Ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05719714
Drug: Dapagliflozin 10 MG [Farxiga]
Normalized name: dapagliflozin 10 MG [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
Study: NCT05896670
Drug: licaminlimab
Normalized name: Licaminlimab
DrugBank: Licaminlimab (DB18936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
Study: NCT04839354
Drug: L-Arginine Hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A one-time L-arginine hydrochloride loading dose of 200 mg/kg will be administered intravenously (IV) followed by a standard dose of 100 mg/kg given by IV three times per day (TID).
Study: NCT06252649
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate-release solid dosage form administered PO.
Study: NCT06252649
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV Q2W.
Study: NCT06252649
Drug: Bevacizumab-awwb
Normalized name: bevacizumab-awwb
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV Q2W.
Study: NCT06092970
Drug: RBT-1
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT06616636
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT05358548
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study: NCT06616636
Drug: Rezatapopt
Normalized name: Rezatapopt
DrugBank: Rezatapopt (DB18980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally with food
Study: NCT05255302
Drug: Pembrolizumab before randomization
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg every 3 weeks before randomization
Study: NCT05255302
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
Study: NCT05255302
Drug: Pembrolizumab after randomization
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg every 3 weeks after randomization
Study: NCT05731492
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan will be administered orally.
Study: NCT06625411
Drug: VRDN-003
Normalized name: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimer
DrugBank: Veligrotug (DB18976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
Study: NCT05358548
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study: NCT05358548
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study: NCT05358548
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is a type of immunotherapy and works by helping your immune system to kill cancer cells
Study: NCT06625398
Drug: VRDN-003
Normalized name: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimer
DrugBank: Veligrotug (DB18976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
Study: NCT06615050
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet or intravenously (IV)
Study: NCT06615050
Drug: Ruxolitinib (Rux)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06615050
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet or intravenously (IV)
Study: NCT06685757
Drug: Felzartamab
Normalized name: Felzartamab
DrugBank: Felzartamab (DB16375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive felzartamab by intravenous infusion.
Study: NCT06682637
Drug: Melflufen
Normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pepaxti 20 mg powder for concentrate for solution for infusion
Study: NCT06682637
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
Study: NCT06682806
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
Study: NCT06556810
Drug: Atibuclimab (IC14)
Normalized name: Atibuclimab
DrugBank: Atibuclimab (DB06546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
Study: NCT03730051
Drug: Gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
Study: NCT03730051
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
Study: NCT06685835
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated Oral tablet
Study: NCT05668026
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
Study: NCT06618001
Drug: JNJ-89853413
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-89853413 will be administered.
Study: NCT06022146
Drug: Rifampin and Isoniazid
Normalized name: Rifampin and Isoniazid Capsules
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3HR regimen of isoniazid and rifampicin once daily for three months
Study: NCT06022146
Drug: isoniazid and rifapentine
Normalized name: Rifapentine
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
Study: NCT06402565
Drug: NOX1416 and SOC
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Nitric Oxide
Study: NCT06051617
Drug: Seladelpar
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis.
Study: NCT05766124
Drug: Tissue Plasminogen Activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapleural administration of tissue plasminogen activator
Study: NCT05094570
Drug: Dupilumab Prefilled Syringe
Normalized name: dupilumab Prefilled Syringe
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab 300 mg
Study: NCT06619080
Drug: Genicular nerve block with bupivacaine and corticosteroids
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.
Study: NCT06619080
Drug: Genicular nerve block with bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.
Study: NCT06619080
Drug: Genicular nerve block with saline
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects.
Study: NCT06693726
Drug: Angiotensin II Infusion
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II continuous infusion
Study: NCT06693752
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Normalized name: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
Study: NCT06683742
Drug: Aflibercept (2.0 mg)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection
Study: NCT06686693
Drug: Injectafer
Normalized name: Injectafer
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injectafer - 15 mg/kg up to 1000 mg
Study: NCT06632327
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give cisplatin
Study: NCT06632327
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give Carboplatin
Study: NCT06632327
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Give Pemetrexed
Study: NCT06632327
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give Gemcitabine
Study: NCT06632327
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give Docetaxel
Study: NCT06632327
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give Vinorelbine
Study: NCT06632327
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Give Nivolumab
Study: NCT06632327
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Give Pembrolizumab
Study: NCT06632327
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give Atezolizumab
Study: NCT06632977
Drug: Valemetostat Tosylate
Normalized name: tazemetostat
DrugBank: Valemetostat (DB18314)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06632977
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06632977
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06632977
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06632977
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06632977
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
Normalized name: lutetium Lu 177 vipivotide tetraxetan
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06700538
Drug: ARO-INHBE
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT06700538
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC injection
Study: NCT05884242
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab will be administered subcutaneously.